The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
''BetterLife is due to start its clinical trials later this fall in Australia for AP-003, BetterLife’s inhaled human interferon alpha 2b, in patients with mild to moderate symptoms of COVID-19.''
Australia? Well good luck with recruiting patient in Australia BetterLife,
Australia has very low covid-19 cases.
Yesterday Australia only have 14 cases, yes 14 cases, I am sure BetterLife are not just 6 months behind us.
''BetterLife is due to start its clinical trials later this fall in Australia for AP-003, BetterLife’s inhaled human interferon alpha 2b, in patients with mild to moderate symptoms of COVID-19.''
Australia? Well good luck with recruiting patient in Australia BetterLife,
Australia has very low covid-19 cases.
IMHO even 20% is a good drug atm,
remdesivir did not improve overall survival,
and only reduced hospital stays to 10 days from 15 days.
dyor, GLA
https://mobile.reuters.com/article/amp/idUSKBN279055
IMHO even 20% is a good drug atm,
remdesivir did not improve overall survival,
and onlty reduced hospital stays to 10 days from 15 days.
dtor, GLA
https://mobile.reuters.com/article/amp/idUSKBN279055
There’s £6m set aside in the placing RNS appendix that has only been broadly explained.
“The Company is also discussing with a number of other research organisations and trial delivery groups in the UK and internationally as to how it could either commence trials of SNG001 or otherwise integrate SNG001 with existing trials.
C. £6m
“Generating further data to support SNG001 clinical development, manufacturing processes and regulatory activities”
MUCH more to come here!
Do you guys think she talking about Synairgen?
>> Patrizia Cavazzoni: Well right now, there are no treatments that have been approved for COVID-19, but we have lots and lots of clinical trials and studies underway. What we have seen so far is many researchers and really wanting to test existing therapies for other conditions, other than COVID, that might be promising for the treatment for COVID, so we have looked at over hundreds of these types of potential therapeutics. What we're also seeing more recently after the wave of interest to look at existing drugs that might be repurposed for COVID, is now a really big push to study treatments that have been developed in a fit for purpose way for COVID. And an example of this is a class of very promising therapies that we hope will make a difference, which consists of antibodies that are developed in a manufacturing facility rather than in the human body, that if they work, will have the ability to neutralize the virus and prevent it from sort of attacking the host. So that's an example of some of these promising therapies that do not represent previously used drugs that might be repurposed for COVID if it turns out that they work in clinical trials that are really developed specifically for COVID.
on 09-09-2020 ''Synairgen IP Update'' RNS
Prior to this in July, Synairgen also submitted a patent application for the use of inhaled interferon beta in COVID-19 patients.
The Company will update the market on the progress of these patent applications as appropriate.
Is it possible that Hospitals and Universities can do trials without patent if it is for study purpose.
Like this one Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study (COV-NI)
What do you guys think?
https://clinicaltrials.gov/ct2/show/NCT04469491
Phase III trial
The trial will enrol 900 patients with an OSCI score of 4 to be randomised:
· 300 patients with one syringe of SNG001;
· 300 patients with two syringes of SNG001; and
· 300 patients with placebo.
20 countries, 900 patients in total, just 45 patients each country, won't take long to fill.
Synairgen is working with Clinigen on this point. In France, nominative ATU status allows access before the MA. However, this implies a restricted access to the hospital, as well as a probable competition with current clinical trials.
https://twitter.com/MARYau_MCU_PH/status/1316353589330300929?s=20
maybe sng001 is gov plan b, if confirm no vaccine available , then bojo will say something like
''we don't have any vaccine available soon, but we have something even better, sng001''
that's maybe the real reason for the radio silent, lol
Pilot phase - 100 patients randomised in the hospital setting, 120 patients randomised in the home setting.
Pivotal phase - estimated at an additional 100 to 300 patients per arm, but the actual number will be determined after the data review at the end of the Pilot phase
so the data review (peer review??) at the end of the Pilot phase.
meaning we are still waiting for the peer review?
also thanks ri PokerJason, because of your link, I found what I was looking for. lol
https://clinicaltrials.gov/ct2/show/NCT04385095